| P50 | author | Oren Zusman | Q56947240 |
| | Mical Paul | Q28037206 |
| P2093 | author name string | Habip Gedik | |
| | Fidi Koppel | |
| | Sergey Altunin | |
| | Yael Dishon Benattar | |
| P2860 | cites work | Conducting Meta-Analyses in R with the metafor Package | Q58423162 |
| | Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis | Q26764796 |
| | GRADE: an emerging consensus on rating quality of evidence and strength of recommendations | Q27860753 |
| | STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship | Q28067215 |
| | Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America | Q29616084 |
| | Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems | Q33623060 |
| | Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections | Q34057525 |
| | Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. | Q34107684 |
| | Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis | Q35101242 |
| | Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections | Q36076006 |
| | Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections | Q36095874 |
| | Combination therapy for treatment of infections with gram-negative bacteria | Q36156077 |
| | Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection | Q36310173 |
| | Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections | Q36933469 |
| | Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies | Q37290159 |
| | Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria | Q37544860 |
| | Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems | Q38126768 |
| | Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence | Q38147851 |
| | Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center | Q39980070 |
| | Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia | Q41218592 |
| | Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. | Q42228164 |
| | Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia | Q42256268 |
| | Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy? | Q42285097 |
| | Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. | Q42627289 |
| | Effectiveness and safety of colistin: prospective comparative cohort study | Q43124623 |
| | Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients | Q43223792 |
| | Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy. | Q44181170 |
| | Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections | Q44483256 |
| | Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options | Q45836707 |
| | Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. | Q45974680 |
| | Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. | Q46198938 |
| | Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii | Q46939760 |
| | Observational studies examining patient management in infectious diseases. | Q54498946 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | carbapenem antibiotic | Q410897 |
| | meta-analysis | Q815382 |
| | systematic review | Q1504425 |
| P304 | page(s) | 29-39 | |
| P577 | publication date | 2016-09-13 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis | |
| P478 | volume | 72 | |